Pearl Therapeutics (Acquired by AstraZeneca)

Biopharmaceutical company that developed inhaled therapies for respiratory diseases including COPD. Acquired by AstraZeneca in 2013 for up to $1.15 billion.

Location
Redwood City, California, USA
Founded
2006
Investors
1
Categories
respiratory, therapeutics, copd, acquired

Investors

NameLocationTypeStagesPortfolio
5AM VenturesMenlo Park, USAbiotech-focused
seedseries-a+1
8